Preoperative Systemic Therapy for Breast Cancer

The indications for preoperative/neoadjuvant systemic therapy in breast cancer have changed over the past few years. In this article, the authors review the current data for use of neoadjuvant therapy in inoperable and operable settings. The evolution of various neoadjuvant regimens used in triple-negative breast cancer, human epidermal growth factor receptor 2 (HER2) overexpressing/gene-amplified (HER2+) tumors, and hormone receptor positive breast cancer is discussed as well as the role of neoadjuvant chemotherapy in tailoring adjuvant treatment.